Arthritis &Rheumatology, EarlyView.Objective Ear, nose, and throat (ENT) manifestations are common in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There is an unmet need for drugs to target these manifestations. Granuloma formation is characteristic of proteinase 3 (PR3)–AAV. In a zebrafish model, niclosamide inhibits PR3‐induced granuloma formation.
Benjamin Lim +4 more
wiley +1 more source
Early success of the COCOON trial: Preventing dermatologic adverse events in first-line EGFR-mutant NSCLC. [PDF]
OncoscienceTiwari B, Koirala A.
europepmc +1 more source
Real-world clinical effectiveness of trimethoprim-sulfamethoxazole for primary prophylaxis of pneumocystis pneumonia in non-hodgkin lymphoma patients treated with rituximab. [PDF]
PLoS OneCharoenrit P, Niparuck P, Rotjanapan P.
europepmc +1 more source
Arthritis &Rheumatology, EarlyView.Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig +5 more
wiley +1 more source
Predicting FVIII Activity in Patients Who Use Recombinant FVIII Fc Fusion Protein for Prophylaxis and Treatment of Bleeding Episodes [PDF]
, 2014 Allen, G +7 more
core
A Metabolomic Signature Predicts Gout Flare Clinical Outcome Associated With Colchicine Prophylaxis
Arthritis &Rheumatology, EarlyView.Objective This study investigated that serum metabolomics, before urate‐lowering therapy (ULT) initiation, could serve as a biomarker for responsiveness to colchicine prophylaxis in patients with gout commencing treat‐to‐target ULT. Methods We studied a multicenter prospective cohort (n = 409) initiating treat‐to‐target ULT plus colchicine prophylaxis.
Wenyan Sun +13 more
wiley +1 more source
Preventing First and Further Decompensation in Advanced Chronic Liver Disease. [PDF]
Liver IntSüffert LC +2 more
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Levofloxacin is a widely used antibiotic included in rifampicin‐resistant tuberculosis (RR‐TB) treatment. Data describing levofloxacin concentrations in breastmilk and infant exposure are limited. We analysed data from two South African studies of breastfeeding women receiving levofloxacin (750–1000 mg daily) for RR‐TB.
Sharon Sawe +9 more
wiley +1 more source
Reconsidering antiviral prophylaxis in HBsAg-negative, anti-HBc-positive patients treated with rituximab. [PDF]
Hepatol CommunPapatheodoridis G, Hwang J.
europepmc +1 more source
Low‐intervention clinical trials in Spain: Do they progress?
British Journal of Clinical Pharmacology, EarlyView.Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza +4 more
wiley +1 more source